Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER: Evolocumab in stable CAD
NCT05152888Phase 4Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in coronary artery disease (CAD) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Coronary Flow Reserve at 52 weeks and Stress Myocardial Blood Flow at 52 weeks. Started Mar 2022; status: recruiting.
02
Drugs
evolocumab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05152888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152888.